The Trump administration issued a final plan for how it will carry out the third round of the Medicare drug price negotiations, pushing forward a Biden-era program despite ongoing opposition from the pharmaceutical industry, Bloomberg’s Nyah Phengsitthy reports. The 381-page final guidance by the U.S. Centers for Medicare & Medicaid Services outlines how the federal government plans to set the prices of up to an additional 15 drugs in the program. The negotiations for the third cycle are slated to begin in 2026 and prices will go into effect in 2028. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Bristol Myers, Takeda, Astex to contribute data for AI tool, Reuters says
- Pfizer Stock (PFE) Climbs after Pricing Deal with Trump, 3-Year Exemption from Pharma Tariffs
- White House announces deal with Pfizer for ‘most-favored-nation pricing’
- Trump says other drugmakers to join Pfizer with ‘most favored nation’ prices
- enGene appoints Sweiti as Chief Medical Officer